Investigational drug · Phase 3
BGB-15025
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
4
Any phase or sponsor naming "BGB-15025"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGB-15025", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Advanced Malignancies
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BGB-15025" as an intervention, largest first.
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05635708 · 418 participants · Start Feb 10, 2023 · Primary completion Dec 19, 2025
Drug: Tislelizumab; BGB-A445 and 7 more · For: Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer
Sites: Los Angeles, California; Boston, Massachusetts; New York, New York · 61 sites in all
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04649385 · 157 participants · Start Mar 4, 2021 · Primary completion Oct 17, 2025
Drug: BGB-15025; Tislelizumab and 7 more · For: Advanced Solid Tumor
Sites: New York, New York; Houston, Texas; San Antonio, Texas · 20 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06029127 · 35 participants · Start Oct 23, 2023 · Primary completion Dec 31, 2024
Drug: Gimistotug; Docetaxel and 1 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.